Chemotherapy-Induced Bone Defects Stem from Skeletal Progenitor Dysfunction
Authors: Tikhonova Anastasia N. , Li Ximing , Aguilar-Navarro Alicia , Nader Mursal , Edun Gibran , Gower Mark , Jahangiri Soheil , Lee Ho Seok , Phillips David-Michael , Fernandez Minerva , Ramkumar Pirakashini , Coutu Daniel , Whyne Cari , Schwartz Gregory , Kislinger Thomas , Akens Margarete 
Published: December 2024

Combination chemotherapy has markedly improved the survival rates among acute lymphoblastic (ALL) leukemia patients (Hunger & Mulligan, NEJM 2015). However, treatment-related long-term morbidities, including skeletal defects, present a significant clinical challenge. Cancer survivors frequently suffer from osteoporosis, increased fracture risk, and, in pediatric cases, height deficit, profoundly impacting their quality of life (Vandecruys et al., J. Pediatr. 2013). The development of interventions to preserve bone is impeded by an incomplete understanding of molecular mechanisms underlying long-term bone toxicity mediated by chemotherapy. Skeletal integrity is maintained by active osteoblasts, which originate from bone marrow (BM) mesenchymal stem and progenitor cells (MSPCs) (Zhou et al., Cell Stem Cell 2014). We previously showed that chemotherapy can induce significant transcriptional reprogramming in MSPCs, leading to a reduction in their osteogenic potential (Tikhonova & Dolgalev et al., Nature 2019). Nevertheless, it remains unclear whether these stress-induced alterations in MSPCs can persist over time and contribute to permanent bone defects.

To examine the long-term impact of chemotherapy on MSPCs, we treated mice with doxorubicin (DOX), an anthracycline prescribed in ALL induction therapy. Mice receiving DOX treatment exhibited short stature, trabecular bone loss, and diminished bone mineral density 20 weeks post-treatment, indicating that DOX alone was adequate to induce long-term skeletal defects in mice. Flow cytometry analysis revealed a marked reduction in the frequency of osteogenic MSPCs in DOX-treated animals. Moreover, we found that in vivo DOX treatment led to MSPC dysfunction, as indicated by loss of ex vivo colony-forming capacity and osteogenic differentiation potential. To map MSPC fate in vivo, we conducted lineage tracing experiments using Lepr-tdT;2.3Col-GFP reporter model. Our results revealed a loss of MSPC-derived osteoblasts in DOX-treated animals. Collectively, these findings indicate the loss of functional MSPCs and a shift in MSPC lineage priming following DOX treatment.

Next, we performed bulk RNA sequencing to investigate DOX-mediated molecular changes in MSPCs. Our analysis showed a decrease in osteogenesis-associated pathways and an upregulation of genes associated with DNA damage response and adipogenesis in MSPCs following DOX treatment. Interestingly, we found upregulation of pathways associated with inflammatory response. It has been shown that chronic inflammation shapes function and fate of stem cells (Matatall et al. Cell Rep. 2016). Thus, this finding offers a critical insight into the mechanisms underlying DOX-mediated MSPC dysfunction. Next, to explore the transcriptional heterogeneity of the BM microenvironment, we performed unbiased single-cell RNA sequencing on BM stromal and endothelial populations. We found an enrichment of adipo-primed MSPCs, a loss of osteo-primed MSPCs, as well as a decrease in genes associated with osteogenesis in both MSPC subsets. We also noted a decrease in the frequency of arteriolar vascular endothelial cells, which are typically maintained by osteo-primed MSPCs (Shen et al. Nature 2021). Moreover, we curated transcription factor (TF) regulon signatures on our dataset with SCENIC (Aibar et al. Nat. Med. 2017) and found that DOX-treated mice had a significant decrease in the activity of TFs promoting osteogenesis. Finally, RNA velocity-based lineage trajectory inference (Bergen et al. Nat. Biotechnol. 2020) revealed impaired transition of MSPCs towards the osteogenic lineage. These results indicate that the DOX-mediated MSPC dysfunction is caused by long-term transcriptional rewiring of MSPCs.

Collectively, our results demonstrate that DOX disrupts MSPC differentiation trajectories through permanent molecular reprogramming, resulting in impaired osteogenesis and enduring skeletal defects. Our current work aims to investigate the role of inflammation in DOX-mediated MSPC dysfunction. We anticipate that when completed, this study will elucidate the mechanisms underlying chemotherapy-induced osteotoxicity and facilitate the development of strategies to enhance skeletal health in cancer survivors.